Gray-Market Prescription Drugs: “Material Differences” and Quality-Control Bypass Render Foreign-Labeled Medicines Non-Genuine Under the Lanham Act; Contributory Liability Requires Knowledge (Not Prior Notice or “Control”)

1. Introduction

In Gilead Sciences, Inc. v. RX Valet, LLC (consolidated interlocutory appeals), the Fourth Circuit affirmed a preliminary injunction entered by the District of Maryland against an “alternative funding program” (“AFP”) ecosystem that imported foreign-market, Gilead-branded HIV medication (including Biktarvy) into the United States for dispensing to U.S. patients. The opinion addresses a recurring modern problem: self-funded employer health plans seeking to reduce domestic drug spend by routing certain brand-name prescriptions into international-sourcing channels.

The immediate catalyst was a Maryland patient (John Doe) who expected domestic Biktarvy but received a Turkish-market version labeled and packaged for Turkey. Gilead investigated and alleged a broader scheme involving: (i) the “Quartet” (Rx Valet, LLC; Advanced Pharmacy, LLC; Affordable Rx; and Gregory Santulli) as the entities arranging and operationalizing foreign fulfillment; and (ii) a third-party administrator (“TPA”) and pharmacy benefit manager (“PBM”) layer (Meritain Health, Inc. and ProAct, Inc.) that allegedly facilitated the program through claim-routing, data feeds, and payment processing.

Key issues included: (1) whether the importation and distribution of authentic but foreign-market Gilead-branded prescription drugs likely constitutes trademark infringement because the products are not “genuine” for Lanham Act purposes; (2) whether the FDCA precludes the Lanham Act claims; (3) whether Meritain and ProAct were likely contributorily liable under Inwood Lab'ys, Inc. v. Inves Lab'ys, Inc.; and (4) whether the Winter v. Nat. Res. Def. Council, Inc. preliminary injunction factors were met, including irreparable harm in light of the Trademark Modernization Act of 2020.

2. Summary of the Opinion

  • Preliminary injunction affirmed. The Fourth Circuit held the district court did not abuse its discretion under Winter v. Nat. Res. Def. Council, Inc. and Fourth Circuit review principles stated in Leaders of a Beautiful Struggle v. Baltimore Police Dep't and Mountain Valley Pipeline, LLC v. 6.56 Acres of Land, Owned by Sandra Townes Powell.
  • Direct infringement (Quartet): likely success. The imported drugs were not “genuine” because they were materially different from U.S.-market versions and also reached consumers outside Gilead’s quality-control system (labeling differences; missing warnings and identifiers; absence of temperature-monitoring protocols; lack of traceability pedigrees; exclusion from recall mechanisms; bypass of authorized distribution network).
  • FDCA does not preclude these Lanham Act claims. The court distinguished claims requiring courts to interpret FDA regulations (e.g., Sandoz Pharms. Corp. v. Richardson-Vicks, Inc.) and “implicit FDA approval” false-advertising theories (e.g., Mylan Laboratories, Inc. v. Matkari), and relied on the complementary framework recognized in POM Wonderful LLC v. Coca-Cola Co..
  • Contributory infringement (Meritain and ProAct): likely success. Under Inwood Lab'ys, Inc. v. Inves Lab'ys, Inc. and the Fourth Circuit’s application in Rosetta Stone Ltd. v. Google, Inc., knowledge can be shown without a rule requiring prior cease-and-desist notice. The panel rejected importing a separate “degree of control” element from Ninth Circuit cases such as Lockheed Martin Corp. v. Network Sols., Inc. and Perfect 10, Inc. v. Visa Int'l Serv. Ass'n.
  • Irreparable harm presumed and not rebutted. Given likely trademark success, 15 U.S.C. § 1116(a) provided a rebuttable presumption of irreparable harm; Gilead’s investigation-related delay did not defeat irreparable harm under principles reflected in Tough Traveler, Ltd. v. Outbound Products.

3. Analysis

3.1. Precedents Cited (and How They Shaped the Holding)

A. Preliminary injunction framework and appellate review

  • Winter v. Nat. Res. Def. Council, Inc. supplied the four-factor test (likelihood of success, irreparable harm, balance of equities, public interest). The opinion treats “likelihood of success” as the central merits gateway.
  • Leaders of a Beautiful Struggle v. Baltimore Police Dep't and Mountain Valley Pipeline, LLC v. 6.56 Acres of Land, Owned by Sandra Townes Powell reinforced deferential abuse-of-discretion review, clear-error review for factfinding, and the “plausible account of the evidence” restraint on appellate reweighing.
  • Salomon & Ludwin, LLC v. Winters anchored de novo review of legal conclusions, which mattered for the doctrinal questions (FDCA preclusion, “genuineness,” and the elements of contributory infringement).
  • Jensen v. Md. Cannabis Admin. and Visual Scis., Inc. v. Integrated Commc'ns Inc. framed the quantum of proof required at the preliminary stage (“likely,” “reasonable probability of ultimate success”).

B. FDCA/Lanham Act relationship

  • POM Wonderful LLC v. Coca-Cola Co. was central to the court’s refusal to infer sweeping FDCA preclusion. The Fourth Circuit adopted the “complementary” statutory view and focused on whether the Lanham Act theory required interpreting FDCA regulations.
  • Sandoz Pharms. Corp. v. Richardson-Vicks, Inc. was distinguished as a case where Lanham Act liability depended on FDA regulatory interpretation (whether an ingredient could be called “inactive”). Here, the infringement theory was “material differences” and quality-control bypass—facts the court could assess without deciding FDCA compliance.
  • Mylan Laboratories, Inc. v. Matkari was distinguished because Gilead did not rely on an “implicit representation of FDA approval” from mere marketing.

C. Gray market goods, “genuineness,” material differences, and quality control

  • K Mart Corp. v. Cartier, Inc. provided the definitional baseline for “gray market goods” (foreign-manufactured goods bearing a valid U.S. trademark imported without trademark holder consent).
  • Shell Oil Co. v. Com. Petroleum, Inc. supplied Fourth Circuit authority for the quality-control doctrine: goods distributed outside the trademark owner’s legitimate quality controls are not “genuine,” even if physically authentic. The opinion uses Shell Oil to reject defendants’ attempt to equate “same chemical formula” with “genuine.”
  • Societe Des Produits Nestle, S.A. v. Casa Helvetia, Inc. was used for the “bundle of characteristics” concept and to support the material-differences principle even when composition is identical.
  • The court canvassed broad circuit support for the material-differences doctrine and cited: Iberia Foods Corp. (as “Iberia Foods Corp. v. Romeo”), Weil Ceramics & Glass, Inc. v. Dash, Brilliance Audio, Inc. v. Haights Cross Commc'ns, Inc., Zino Davidoff SA v. CVS Corp., Original Appalachian Artworks, Inc. v. Granada Electronics, Inc., and Lever Brothers Co. v. United States. These cases collectively supported two propositions adopted here: (i) the materiality threshold is low (“slight difference” relevant to consumers); and (ii) packaging, language, inserts, service/fulfillment limitations, and labeling differences can be material even if the product itself is chemically/physically the same.
  • El Greco Leather Prods. Co. v. Shoe World, Inc. supported the central importance of trademark-owner quality control as a protected interest.
  • Am. Petroleum Inst. v. Cooper was cited to emphasize that the inquiry is compliance with the owner’s quality controls, not proof of actual inferiority.
  • Matrix Essentials, Inc. v. Emporium Drug Mart, Inc. was used to explain the “latent defect” theory: consumer confusion exists because consumers cannot detect whether quality protocols were followed.
  • NEC Electronics v. CAL Circuit Abco was addressed and confined to its context (identical chips under common control), not a situation where imported goods materially differ and bypass domestic distribution quality controls.

D. Direct infringement elements

  • Rosetta Stone Ltd. v. Google, Inc. and Lamparello v. Falwell provided the Fourth Circuit formulation of trademark infringement elements (ownership, use in commerce without consent, in connection with goods/services, and likelihood of confusion).

E. Contributory trademark infringement: knowledge, willful blindness, and rejection of “notice-only” and “control” add-ons

  • Inwood Lab'ys, Inc. v. Inves Lab'ys, Inc. supplied the governing standard: contributory liability where a defendant intentionally induces infringement or continues supplying products/services to one it knows or has reason to know is infringing.
  • Rosetta Stone Ltd. v. Google, Inc. was pivotal because it applied Inwood to a service provider and rejected “general knowledge” as insufficient while requiring supply to “identified individuals” known/reason-known to infringe (with an evidentiary emphasis on what shows knowledge, not a categorical pre-suit notice rule).
  • Sony Corp. of Am. v. Universal City Studios, Inc. was cited for the “identified individuals” concept referenced in Rosetta Stone.
  • Tiffany (NJ) Inc. v. eBay Inc. was treated as consistent with a “particular listings/particular infringers” knowledge requirement but not as imposing a “prior notice required” element; the opinion also cited Luxottica Grp., S.p.A. v. Airport Mini Mall, LLC for the proposition that trademark holders need not bear the entire notice burden and that willful blindness can establish constructive knowledge.
  • Al-Sabah v. World Bus. Lenders, LLC was cited for willful blindness (“suspicion aroused” and deliberate avoidance of inquiry).
  • Ives Lab'ys, Inc. v. Darby Drug Co. was used to illuminate what the Supreme Court in Inwood “approve[d]” (Judge Friendly’s articulation), underscoring that “reason to know” extends beyond explicit notice.
  • On the proposed “control” requirement, the court discussed out-of-circuit lines: Hard Rock Cafe Licensing Corp. v. Concession Services, Inc., Fonovisa, Inc. v. Cherry Auction, Inc., Lockheed Martin Corp. v. Network Sols., Inc., and Perfect 10, Inc. v. Visa Int'l Serv. Ass'n. The Fourth Circuit declined to add “direct control and monitoring” as a separate element, holding contributory liability in the circuit remains governed by Inwood as applied in Rosetta Stone.

F. Irreparable harm, delay, and trademark presumptions

  • The court relied on the Trademark Modernization Act of 2020 (15 U.S.C. § 1116(a)) and invoked prior Fourth Circuit recognition that “irreparable injury regularly follows” from trademark infringement (citing Lone Star Steakhouse & Saloon, Inc. v. Alpha of Va., Inc.).
  • Tough Traveler, Ltd. v. Outbound Products was applied to reject the argument that investigation-driven delay negates irreparable harm.

G. Appellate jurisdiction (side issue)

  • The panel declined pendent appellate jurisdiction over the personal jurisdiction denial under the framework in Rux v. Republic of Sudan, Indus. Servs. Grp., Inc. v. Dobson, and Scott v. Fam. Dollar Stores, Inc.. It also deemed waived an argument that the district court needed to find a “reasonable probability” of personal jurisdiction for preliminary relief because it was not raised below (citing In re Under Seal), while noting personal jurisdiction is waivable (citing al-Suyid v. Hifter and Grayson v. Anderson).

3.2. Legal Reasoning

A. The central merits move: “authentic” is not necessarily “genuine”

A critical conceptual pivot is the court’s separation of authenticity (genuine manufacturing and non-counterfeit marks) from genuineness for Lanham Act purposes. The Turkish Biktarvy was “authentic” in that it bore legitimate marks, was authorized by Gilead for manufacture, and was chemically identical. But the court held those facts do not end the infringement inquiry because gray-market goods can still be non-genuine if they (i) materially differ from U.S.-authorized goods or (ii) bypass the trademark owner’s legitimate quality controls.

B. Material differences: the court treats drug labeling and patient information as “product characteristics”

The opinion treats what accompanies a prescription drug—label language, warnings, regulatory disclosures, and identifiers—as consumer-relevant product attributes. The court catalogued concrete divergences: Turkish-language labeling; omitted “Rx only”; absence of the NDC number; omitted warnings and storage instructions; and the absence of FDA-approved patient information (including a “black box” warning, FDA contact information, and a manufacturer hotline). Applying the “low threshold of materiality” articulated in Zino Davidoff SA v. CVS Corp., the panel concluded these are plainly material, particularly in the prescription-drug context where warnings and standardized identifiers are central to patient safety and consumer expectations.

Notably, the court rejected the argument that consumers can “look up” missing information online. The legal question is whether the consumer receives “exactly the bundle of characteristics” expected under the mark (from Societe Des Produits Nestle, S.A. v. Casa Helvetia, Inc.), not whether a motivated consumer can reconstruct the missing bundle after delivery.

C. Quality control: safeguarding temperature, traceability, and recalls is part of the trademarked “promise”

Beyond labels, the opinion grounds non-genuineness in distribution safeguards: domestic shipments are sealed, temperature-controlled and monitored; “quality events” are investigated if thresholds are exceeded; U.S. distribution uses pedigrees for chain-of-custody traceability; and recall protocols are targeted domestically. Imported foreign-market product shipped through unauthorized pathways is outside those systems, and Gilead cannot verify travel conditions, trace custody, or ensure recall notification. Under Shell Oil Co. v. Com. Petroleum, Inc., the question is not whether the product is in fact degraded, but whether it reached consumers under the trademark owner’s “established, legitimate, substantial, and nonpretextual” quality controls (language drawn via Zino Davidoff SA v. CVS Corp. and consistent with El Greco Leather Prods. Co. v. Shoe World, Inc. and Am. Petroleum Inst. v. Cooper).

The court also rejected the defense that the Quartet’s substitute controls were “similar or better.” Trademark law protects the owner’s right to control the quality associated with its marks, not the defendant’s right to implement an alternative system and still use the owner’s trademark.

D. FDCA preclusion: the court narrows to “does the Lanham claim require the court to enforce the FDCA?”

The court’s preclusion analysis is pragmatic: if adjudicating the Lanham Act claim would require deciding technical FDCA compliance questions committed to FDA discretion, preclusion concerns rise (as in Sandoz Pharms. Corp. v. Richardson-Vicks, Inc.). But where the Lanham Act claim turns on marketplace confusion caused by material differences and quality-control bypass, it can be adjudicated without interpreting FDA regulations, even if the facts overlap with FDCA-regulated areas. In that sense, POM Wonderful LLC v. Coca-Cola Co. provides the statutory “coexistence” framing and the court applies it to prescription drugs without adopting an across-the-board rule.

E. Contributory infringement: the Fourth Circuit rejects “prior notice only” and refuses to add an independent “control” element

On contributory liability, the court reads Inwood Lab'ys, Inc. v. Inves Lab'ys, Inc. as written: knowledge or reason to know, not a rigid requirement of pre-suit notice from the mark owner. The panel emphasized constructive knowledge and willful blindness (supported by Luxottica Grp., S.p.A. v. Airport Mini Mall, LLC and the willful blindness definition in Al-Sabah v. World Bus. Lenders, LLC), and treated Tiffany (NJ) Inc. v. eBay Inc. as consistent with requiring knowledge tied to specific infringers/instances, not as mandating a cease-and-desist prerequisite.

The court then declines to adopt a separate “degree of control” element for service providers, notwithstanding Ninth Circuit formulations in Lockheed Martin Corp. v. Network Sols., Inc. and Perfect 10, Inc. v. Visa Int'l Serv. Ass'n. In the Fourth Circuit, the governing test remains Inwood as applied in Rosetta Stone Ltd. v. Google, Inc..

F. Applying the standards to Meritain and ProAct: “knowledge” supported by internal documentation and operational role

The opinion is evidentiary in tone: internal emails and testimony suggested Meritain processed invoices for internationally sourced drugs despite a written policy, recognized those invoices as “internationally sourced meds,” and discussed marketing materials contradicting a supposed refusal to support international sourcing. ProAct, for its part, allegedly programmed “system edits” routing claims to Rx Valet, processed and paid claims for internationally sourced Gilead-branded drugs, and possessed information (including an FDA warning-letter context involving CanaRx) indicating imported drugs could differ in labeling and warnings. This record supported the “knows or has reason to know” prong.

3.3. Impact

A. Gray-market pharmaceuticals in the Fourth Circuit: trademark claims can police international sourcing even when the FDA declines enforcement

The opinion meaningfully strengthens the trademark toolkit against AFP-based importation of foreign-market prescription drugs. Even where the FDA “declined to take enforcement action,” the court confirms that trademark law can still address consumer confusion caused by foreign-language labeling, missing inserts, and quality-control bypass. That elevates Lanham Act litigation (and especially preliminary injunction practice) as a practical enforcement pathway for manufacturers confronting international-sourcing programs.

B. Expansion-by-application of the “material differences” doctrine to prescription-drug distribution

Although the court noted it had not previously applied the material-differences doctrine in a gray-market case, it aligned with the “nearly every court of appeals” consensus and applied it to drugs in a way that treats regulatory labeling, NDC identifiers, warning content, and recall/traceability infrastructure as consumer-relevant “product characteristics.” Future defendants should expect “chemical identity” arguments to carry limited weight when the surrounding consumer-facing and safety-related attributes diverge.

C. Contributory liability risk for TPAs/PBMs and other intermediaries

The opinion signals that intermediaries who provide routing, eligibility feeds, claims edits, and payment processing can face contributory exposure if the record supports knowledge (actual or constructive) that identified partners are distributing non-genuine gray-market drugs. The refusal to impose a “prior notice” prerequisite and the rejection of a freestanding “control” element broaden potential plaintiffs’ ability to plead and prove contributory infringement against sophisticated healthcare-administration entities.

D. Preliminary injunction leverage and irreparable harm presumptions

By invoking the Trademark Modernization Act presumption (15 U.S.C. § 1116(a)) and discounting investigation-driven delay, the decision may make early injunctive relief more attainable in gray-market drug cases—particularly where the plaintiff can marshal concrete labeling/insert discrepancies and quality-control evidence.

4. Complex Concepts Simplified

  • Gray market goods: Authentic branded goods made for sale in one country but imported into another without the trademark owner’s consent (see K Mart Corp. v. Cartier, Inc.).
  • “Genuine” under the Lanham Act: Not the same as “non-counterfeit.” Goods can be authentic yet “non-genuine” if they materially differ from authorized domestic goods or bypass the owner’s quality controls.
  • Material differences doctrine: Even a “slight difference” that consumers would likely consider relevant can defeat genuineness and create likelihood of confusion (see Zino Davidoff SA v. CVS Corp.).
  • Quality-control doctrine: Trademark owners may insist goods bearing their marks reach consumers through their legitimate quality system; bypass can itself create confusion risk (see Shell Oil Co. v. Com. Petroleum, Inc.).
  • First sale (exhaustion) doctrine: Trademark rights are generally “exhausted” after an authorized first sale, but only as to genuine goods; it does not protect resale/importation of non-genuine goods (see Davidoff & Cie, S.A. v. PLD Int'l Corp.).
  • Contributory trademark infringement: Liability for those who facilitate infringement by others, if they intentionally induce it or continue supplying services to someone they know or have reason to know is infringing (see Inwood Lab'ys, Inc. v. Inves Lab'ys, Inc. and Rosetta Stone Ltd. v. Google, Inc.).
  • Willful blindness: A form of constructive knowledge: suspicion plus deliberate avoidance of confirming facts (see Al-Sabah v. World Bus. Lenders, LLC).
  • FDCA preclusion (in this context): A court may decline Lanham Act claims that would effectively require private enforcement or interpretation of unsettled FDA regulatory questions, but not where the Lanham claim can be decided on confusion/material-differences grounds (see POM Wonderful LLC v. Coca-Cola Co.).
  • TPA/PBM/AFP (operational roles): A TPA administers self-funded plans; a PBM manages pharmacy benefits and claim edits; an AFP offers a separate channel that sources certain drugs internationally, often outside domestic pharmacy networks.

5. Conclusion

The Fourth Circuit’s decision affirms a robust trademark-based constraint on AFP-driven importation of foreign-market prescription drugs. The court held that even authentic foreign-manufactured medication may be “non-genuine” under the Lanham Act when it arrives with foreign-language labeling, missing warnings and identifiers, and outside the manufacturer’s domestic quality-control ecosystem (temperature monitoring, traceability, and recall systems). The opinion also clarifies contributory trademark principles in the circuit: knowledge (including constructive knowledge and willful blindness) can suffice without a categorical “prior notice” rule, and the Fourth Circuit declines to graft a separate “degree of control” element onto Inwood.

In practical terms, the ruling increases litigation exposure for international-sourcing networks and for the administrative intermediaries that route claims and payments into those channels, and it strengthens manufacturers’ ability to obtain early injunctive relief where the record demonstrates material differences and quality-control bypass.